DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA).

Trial Profile

DHEA Against Vaginal Atrophy (Placebo-controlled, Double-blind and Randomized Phase III Study of 3-month Intravaginal DHEA).

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Prasterone (Primary)
  • Indications Atrophic vaginitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Sep 2011 Planned End Date changed from 1 Sep 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Status changed from recruiting to active, no longer recruiting, as reported by the ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top